Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash & Equivalents (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Cash & Equivalents for 10 consecutive years, with $421.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 141.95% to $421.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $421.0 million, a 141.95% increase, with the full-year FY2025 number at $421.0 million, up 141.95% from a year prior.
  • Cash & Equivalents was $421.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $202.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $480.7 million in Q2 2024 to a low of $72.6 million in Q3 2023.
  • A 5-year average of $216.9 million and a median of $175.2 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 81.47% in 2023, then skyrocketed 371.0% in 2024.
  • Ultragenyx Pharmaceutical's Cash & Equivalents stood at $307.6 million in 2021, then crashed by 56.78% to $132.9 million in 2022, then soared by 60.97% to $214.0 million in 2023, then fell by 18.69% to $174.0 million in 2024, then skyrocketed by 141.95% to $421.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Cash & Equivalents are $421.0 million (Q4 2025), $202.5 million (Q3 2025), and $176.3 million (Q2 2025).